Recent Posts

I fully expect for the results to be released on a national holiday when markets are closed, Will it be Juneteeth or July 4? Even as 67,000 people have viewed this thread not a single person has offered any counter argument saying the results are positive. That says it all! What could the fall out be if the results are really really bad?

We have quite an intriguing situation! To summarize, we've recently seen the departure of three of our top account managers; this year’s award winners?!? This is quite a shake-up for the team. The latest exit is especially noteworthy; it’s the National Account Director (NAD) who was just a few weeks ago extolling the virtues of Bayer as an exemplary workplace on a panel. It’s almost laughable to think about it in light of their abrupt departure. The entire NAD team and more than half the RAD team interviewing for new jobs!!! Honestly, navigating the daily challenges here feels like it demands a good sense of humor just to withstand the storms we face. The unfortunate truth is that our leadership is clearly floundering without a clear sense of direction or support, leaving many of us feeling adrift and uninspired. Makes you wonder if they even care or are looking for new jobs as well?

anonymous said:

That is the point I guess!
Market (not payer- because they are acutely aware of indication they are paying for) confusing that CVOT benefit is due to weight loss
However CVOT benefit independent of weight loss is what Wegovy does, and Zepbound doesn’t.

Click to expand...

Ok

100%
Poor leadership that stems from the top at the Home Office.

Bad reputation, the second I say I work for Applied it gets embarrassing.

This disaster is on the leadership team. They wanted to launch Wegovy as quickly as possible only to runout of supply 3 months later. Then we had to sell Saxenda again for another year while supply was built back up. Only supply ran out again. We launched a drug in June of 2021 and didn’t have consistent supply until March 2025. They also completely underestimated the compounded Semaglutide market even though reps kept bringing it up. Lastly, no innovation as we watched LillyDirect take over the cash market. But, blame the reps for not selling enough and cut them while home office is bloated and laughs during conference calls when we had no supply.